Known more for its use as party drug, ketamine can provide a lifeline for people experiencing distressing mental health ...

Harrow, Inc. (NASDAQ: HROW), a U.S.-based provider of ophthalmic disease management solutions, announced on Friday that it ...

The acquisition will include Melt’s lead investigational therapy, MELT-300, designed to provide rapid, predictable sedation ...

Harrow plans to submit a New Drug Application (“NDA”) to the FDA in 2027, with a potential U.S. commercial launch in 2028.